Activation of monocyte-mediated tumoricidal activity in patients with acquired immunodeficiency syndrome

E. S. Kleinerman, L. M. Ceccorulli, L. A. Zwelling, T. Twilley, R. B. Herberman, J. Jacob, E. P. Gelmann

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

The purpose of these studies was to determine whether peripheral blood monocytes from acquired immunodeficiency syndrome (AIDS) patients with Kaposi's sarcoma could be activated to lyse human tumor target cells in vitro. Monocytes were isolated and incubated for 24 hours in vitro with either medium (control), a crude mitogen-induced lymphokine preparation (MAF), or endotoxin before the addition of [125I]IUdR-labeled A375 melanoma target cells. Cytolysis was determined 72 hours later. Twelve (100%) of 12 patients tested had monocyte-mediated cytotoxicity values that were comparable to those of normal individuals. Recombinant human gamma interferon (IFN(γ)) activated both normal and AIDS monocyte-mediated tumoricidal function only when combined with lipopolysaccharide (LPS). In addition, mononuclear cells from 10 AIDS patients were also tested for their ability to secrete MAF and IFN(γ) in response to a mitogenic stimulus. Lymphokines generated from all 10 patients contained substantial amounts of IFN(γ) (100 to 2,500 U/mL); however, 3 of these 10 lymphokine preparations failed to activate normal monocytes to lyse tumor cells. These results suggest that monocyte-mediated tumoricidal function of AIDS patients is intact and thus suggest new approaches for the therapy of AIDS.

Original languageEnglish (US)
Pages (from-to)1005-1012
Number of pages8
JournalJournal of Clinical Oncology
Volume3
Issue number7
DOIs
StatePublished - 1985
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Activation of monocyte-mediated tumoricidal activity in patients with acquired immunodeficiency syndrome'. Together they form a unique fingerprint.

Cite this